Search research articles
Contact Us
Filters
Showing results (11-20 of 25) with videos related to
Page
of 3
Sort By:
BJU International
|
February 26, 2009
Is there a rationale for the chronic use of phosphodiesterase-5 inhibitors for lower urinary tract symptoms secondary to benign prostatic hyperplasia?
Thierry Roumeguère, K Zouaoui Boudjeltia, Claude Hauzeur, et al.
European Urology
|
March 15, 2006
EAU Guidelines on erectile dysfunction: an update
Eric Wespes, Edouard Amar, Dimitrios Hatzichristou, et al.
European Urology
|
September 30, 2006
Presence of LDL modified by myeloperoxidase in the penis in patients with vascular erectile dysfunction: a preliminary study
Karim Zouaoui Boudjeltia, Thierry Roumeguere, Paul Delree, et al.
The Journal of Sexual Medicine
|
January 21, 2006
Sexual intercourse attempt patterns with two dosing regimens of tadalafil in men with erectile dysfunction: results from the SURE study in 14 European countries
Ignacio Moncada, Jan-Erik Damber, Vincenzo Mirone, et al.
European Urology
|
June 5, 2012
EAU guidelines on penile curvature
Konstantinos Hatzimouratidis, Ian Eardley, François Giuliano, et al.
European Urology
|
December 10, 2013
European Association of Urology guidelines on priapism
Andrea Salonia, Ian Eardley, François Giuliano, et al.
European Urology
|
March 2, 2010
Guidelines on male sexual dysfunction: erectile dysfunction and premature ejaculation
Konstantinos Hatzimouratidis, Edouard Amar, Ian Eardley, et al.
Free Radical Research
|
September 19, 2019
HO-1 mitigates acute kidney injury and subsequent kidney-lung cross-talk
Maxime Rossi, Sandrine Delbauve, Thierry Roumeguère, et al.
Biochemical and Biophysical Research Communications
|
August 14, 2018
Dual effect of hemin on renal ischemia-reperfusion injury
Maxime Rossi, Sandrine Delbauve, Eric Wespes, et al.
European Urology
|
February 3, 2009
Effects of phosphodiesterase inhibitors on the inflammatory response of endothelial cells stimulated by myeloperoxidase-modified low-density lipoprotein or tumor necrosis factor alpha
Thierry Roumeguère, Karim Zouaoui Boudjeltia, Sajida Babar, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 25) with videos related to
Sort By:
Page
of 3
BJU International
|
February 26, 2009
Is there a rationale for the chronic use of phosphodiesterase-5 inhibitors for lower urinary tract symptoms secondary to benign prostatic hyperplasia?
Thierry Roumeguère, K Zouaoui Boudjeltia, Claude Hauzeur, et al.
European Urology
|
March 15, 2006
EAU Guidelines on erectile dysfunction: an update
Eric Wespes, Edouard Amar, Dimitrios Hatzichristou, et al.
European Urology
|
September 30, 2006
Presence of LDL modified by myeloperoxidase in the penis in patients with vascular erectile dysfunction: a preliminary study
Karim Zouaoui Boudjeltia, Thierry Roumeguere, Paul Delree, et al.
The Journal of Sexual Medicine
|
January 21, 2006
Sexual intercourse attempt patterns with two dosing regimens of tadalafil in men with erectile dysfunction: results from the SURE study in 14 European countries
Ignacio Moncada, Jan-Erik Damber, Vincenzo Mirone, et al.
European Urology
|
June 5, 2012
EAU guidelines on penile curvature
Konstantinos Hatzimouratidis, Ian Eardley, François Giuliano, et al.
European Urology
|
December 10, 2013
European Association of Urology guidelines on priapism
Andrea Salonia, Ian Eardley, François Giuliano, et al.
European Urology
|
March 2, 2010
Guidelines on male sexual dysfunction: erectile dysfunction and premature ejaculation
Konstantinos Hatzimouratidis, Edouard Amar, Ian Eardley, et al.
Free Radical Research
|
September 19, 2019
HO-1 mitigates acute kidney injury and subsequent kidney-lung cross-talk
Maxime Rossi, Sandrine Delbauve, Thierry Roumeguère, et al.
Biochemical and Biophysical Research Communications
|
August 14, 2018
Dual effect of hemin on renal ischemia-reperfusion injury
Maxime Rossi, Sandrine Delbauve, Eric Wespes, et al.
European Urology
|
February 3, 2009
Effects of phosphodiesterase inhibitors on the inflammatory response of endothelial cells stimulated by myeloperoxidase-modified low-density lipoprotein or tumor necrosis factor alpha
Thierry Roumeguère, Karim Zouaoui Boudjeltia, Sajida Babar, et al.
Page
of 3